FDA issues warning to controversial Houston cancer doctor

FDA issues warning to controversial Houston cancer doctor

In letters to Burzynski and his research institute posted online Wednesday, the FDA says that Burzynski inflated success rates for experimental drugs that he calls antineoplastons. The FDA also says Burzynski failed to report side effects and to

10
Like
Save

Comments

Write a comment

*